Efficacy and Safety of Cariprazine, Asenapine, Xanomeline-Trospium, and Lumateperone for Acute Exacerbations of Schizophrenia in Adults: A Network Meta-Analysis.

ABSTRACT:

Objective

This network meta-analysis evaluated the efficacy and safety of cariprazine, asenapine, xanomeline-trospium chloride, and lumateperone in treating acute exacerbations of schizophrenia in adults, compared with placebo.

Methods

A systematic search of PubMed, Scopus, Cochrane Central, and ClinicalTrials.gov identified 12 randomized controlled trials (RCTs; n = 4584 patients). Efficacy was assessed using changes in Positive and Negative Syndrome Scale (PANSS) total scores; safety outcomes included adverse events (AEs), treatment discontinuation, and specific side effects.

Results

Asenapine (MD = -9.83; 95% CI, -13.49 to -6.18), xanomeline-trospium (MD = -9.80; 95% CI, -13.00 to -6.60), and cariprazine (MD = -8.41; 95% CI, -11.33 to -5.50) showed statistic

SUBMITTER: Abusalameh A 

PROVIDER: S-EPMC12617147 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature